0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > KIR2DL2

KIR2DL2

Brief Information

Name:Killer cell immunoglobulin-like receptor 2DL2
Target Synonym:CD158b1 Antigen,CD158b,P58.2,Receptors, KIR2DL2,CD158k,Cl-43,p58 NK receptor CL-43,CD158B1,Natural killer-associated transcript 6,NKAT6,Killer cell immunoglobulin-like receptor 2DL2,KIR2DL2,Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 2,Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 2,P58 Natural Killer Cell Receptor Clone CL-43,CD158 Antigen-Like Family Member B1,MHC Class I NK Cell Receptor,NKAT-6
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
KI2-H5255 Human Human KIR2DL2 / CD158b1 / NKAT-6 Protein, Fc Tag
KI2-H5255-structure
KI2-H5255-sds
ACRO Quality

Part of Bioactivity data

KI2-H5255-SPR
 KIR2DL2 SPR

Biotinylated Biotinylated Human HLA-C*07:02:01 & B2M & RYR ,His,Avitag™&Tag Free (Cat. No. HLR-H52W2) immobilized on SA Chip can bind Human KIR2DL2, Fc Tag (Cat. No. KI2-H5255) with an affinity constant of 1.01 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

KI2-H5255-ELISA
 KIR2DL2 ELISA

Immobilized Human KIR2DL2, Fc Tag (Cat. No. KI2-H5255) at 1 μg/mL (100 μL/well) can bind Lirilummab with a linear range of 0.2-8 ng/mL (QC tested).

Synonym Name

CD158b1

Background

Killer cell immunoglobulin-like receptor 2DL2(KIR2DL2), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. KIR2DL2 and KIR2DL3, regulate the activation of natural killer cells (NK) by interacting with the human leukocyte antigen-C1 (HLA-C1) group of molecules. KIR2DL2, KIR2DL3 and HLA-C1 are highly polymorphic, with this variation being associated with differences in the onset and progression of some human diseases.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lirilumab IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 Phase 2 Clinical Novo Nordisk A/S Leukemia; Bone Marrow Neoplasms; Squamous Cell Carcinoma of Head and Neck; Leukemia, Lymphoid; Hodgkin Disease; Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma; Urinary Bladder Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Biphenotypic, Acute Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken